Facebook
Twitter
LinkedIn
ForwardGrand Rounds in Urology Volume 13, Issue 1
Program Overview:
Prostate cancer (PCa) is associated with the second highest number of cancer related deaths in men, second only to skin cancer. It is the most commonly diagnosed problem with the genitourinary tract and approximately one in six men will be diagnosed with PCa in his lifetime. It is estimated more than 180,000 new cases of prostate cancer will be diagnosed by the end of 2016 as well as more than 26,000 deaths from the disease, according to the National Cancer Institute (NCI). However, the prognosis for most prostate cancers is good, with a 5-year survival rate of 98%. Prostate cancer is generally slow to progress and usually not life-threatening.
Although prostate cancer is a leading cause of cancer deaths among men, the majority of prostate tumors are indolent and associated with little risk to health or longevity. The dilemma arises from the difficulty in distinguishing between aggressive and indolent tumors as crucial medical decisions are being made, especially for the approximately 205,000 men annually with biopsy Gleason scores of 3+3 and 3+4 who must evaluate their treatment options. Currently about 87% of these men with early stage prostate cancer elect aggressive therapy, although only 3-7% progress over their lifetime. Aggressive therapy, most often in the form of radical prostatectomy or radiation, has significant side effects, such as incontinence and impotence, so addressing this significant over treatment is critical. This calls for an effective way of diagnosing and treating PCa at all stages.
In this CME activity, leading experts in prostate cancer will review changes in the treatment paradigm, optimal treatment options, and data from recent clinical trials. The goal of this educational program is to equip urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the treatment of prostate cancer with the up-to-date clinical knowledge and tools they need to best treat their patients.
CME and Support Information:
This continuing medical education activity is provided by The Medical College of Wisconsin and Carden Jennings Publishing. This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals.
Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and Carden Jennings Publishing. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
Target Audience
This activity has been developed and is intended for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the treatment of prostate cancer.
Learning Objectives
Upon successful completion of this educational activity, participants should be better able to:
- Assess the use and sequencing of multiple therapies for advanced and castration resistant prostate cancer
- Discuss the complex issues surrounding use of radiopharmaceuticals in treating advanced prostate cancer
- Discuss how to incorporate the multidisciplinary approach to the treatment of prostate cancer.
PASSWORD FOR POSTTEST IS: V13I1
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
E. David Crawford, MD, discloses that he has received consulting, advisor, meeting participant or lecturer fees from Bayer Healthcare. He discloses that he has received consulting or advisor fees from MDx, Genomic Health, Janssen, Dendreon, and Ferring. He has received scientific study or trial funding from the NIH and the University of Colorado Cancer Center. He discloses also that his wife is an employee of Dendreon.
Phillip J. Koo, MD, discloses that he has received honorarium/ advisory board/speaker fees from Bayer Healthcare.
Daniel P. Petrylak, MD, discloses that he has received consulting fees from Bayer, Bellicum, Dendreon, Exelixis, Ferring, Johnson & Johnson, Medivation, Millennium, Pfizer, Roche Laboratories, Sanofi Aventis, and Tyme Pharmaceuticals. He discloses that he has received grant support from Agenysis, Celgene, Dendreon, Eli Lilly, Johnson & Johnson, Millennium, OncoGenex, Progenics, Roche Laboratories, and Sanofi. Aventis. He discloses that he owns stock in Bellicum and Tyme.
Neil D. Shore, MD, FACS, discloses he has had a consultant or advisory relationship with Astellas, Bayer, Bayer AS (formerly Algeta ASA), Ferring, Janssen, Dendreon, Pfizer, BN Immunotherapeutics, Medivation, Millennium, and Sanofi.
Available Credit
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.